Premium
Dietary tocotrienols improve glucose homeostasis and bone turnover biomarkers in high‐fat‐diet‐ induced obese male mice
Author(s) -
Shen ChwanLi Leslie,
Kaur Gurvinder,
Ramalingam Latha,
Tomison Michael D,
Chung Eunhee,
MoustaidMoussa Naima,
Guo Chun,
Web Cynthia Reinoso,
Mo Huanbiao,
Dufour Jannette D
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.692.2
Subject(s) - medicine , endocrinology , bone remodeling , glucose homeostasis , insulin resistance , bone resorption , n terminal telopeptide , type 2 diabetes , osteoporosis , diabetes mellitus , glycemic , homeostasis , impaired glucose tolerance , chemistry , osteocalcin , alkaline phosphatase , biochemistry , enzyme
Diabetes is a risk factor for osteoporosis. It is critical to emphasize the importance of glycemic control during osteoporosis treatment in patients with type 2 diabetes (T2D). However, diabetic therapies have potentially adverse effects on bone metabolism. In this study, we evaluated the effects of dietary tocotrienols (TT) on glucose homeostasis and bone turnover biomarkers in high‐fat‐diet‐induced obese male mice. Fifty‐eight male C57BL/6J mice were divided into 5 groups: low‐fat diet (LFD), high‐fat diet (HFD), HFD+400 mg TT/kg (lowTT), HFD+1600 mg TT/kg (highTT), and HFD+200 mg metformin/kg (Met, used as a T2D positive control treatment) for 14 weeks. Compared to the LFD group, the HFD group had greater body weight, hyperglycemia, insulin resistance, lower serum procollagen I intact N‐terminal propeptide (P1NP, bone formation marker), and higher serum collagen type 1 cross‐linked C‐telopeptide (CTX, bone resorption marker). Relative to the HFD group, TT supplementation (1) improved glucose homeostasis by lowering 2‐hour fasting blood glucose levels from both glucose tolerance test (369.3±22.6, 285.1±20.5, 228.8±18.9 mg/dL for HFD, low TT, and high TT, respectively) and insulin tolerance test (relative to time zero: HFD: 53.1%, low TT: 47.6%, high TT: 42.9%) in a dose‐dependent manner, (2) increased P1NP concentrations, and (3) decreased CTX levels. There were no significant differences in glucose homeostasis and bone markers between the HFD and the Met groups. This study demonstrates that the protective effect of tocotrienols on bone turnover biomarkers that may be mediated in part through improved glucose homeostasis in T2D animals. Support or Funding Information Funded by American River Nutrition, Inc.